|
Market Closed -
OTC Markets
23:57:00 17/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 15.19 USD | +2.86% |
|
+6.82% | +14.30% |
| 09-01 | Global pharma companies that have publicly announced Trump drug pricing agreements | RE |
| 09-01 | White House Cuts Deal to Lower Prescription Drug Prices With Nine Companies | MT |
| Market Cap | 4,240B 27.22B 23.7B 22.43B 20.38B 38.08B 2,606B 38.27B 267B 103B 1,325B 102B 99.96B | P/E 2027 * |
11.3x | P/E 2028 * | 11.9x |
|---|---|---|---|---|---|
| Enterprise Value | 4,181B 26.84B 23.37B 22.12B 20.1B 37.55B 2,570B 37.73B 263B 102B 1,306B 101B 98.57B | EV / Sales 2027 * |
1.79x | EV / Sales 2028 * | 1.72x |
| Free-Float |
98.92% | Yield 2027 * |
3.39% | Yield 2028 * | 3.51% |
| Markets | Quality | ||
|---|---|---|---|
OTC Markets
| ALPMY | Delayed | |
Deutsche Boerse AG
| YPHA | Delayed |
Last Transcript: Astellas Pharma Inc.
| 1 day | +2.86% | ||
| 1 week | +6.82% | ||
| Current month | +2.77% | ||
| 1 month | +6.00% | ||
| 3 months | +14.21% | ||
| 6 months | +0.26% | ||
| Current year | +14.30% |
| 1 week | 14.37 |  | 15.42 |
| 1 month | 13.92 | | 16.01 |
| Current year | 12.82 | | 17.35 |
| 1 year | 10.03 | | 17.35 |
| 3 years | 8.37 | | 17.35 |
| 5 years | 8.37 | | 18.18 |
| 10 years | 8.37 | | 18.46 |
| Manager | Title | Age | Since |
|---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 64 | 10/02/2023 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 54 | 01/11/2023 |
Tatjana Dragovic
CMP | Compliance Officer | - | 01/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kenji Yasukawa
CHM | Chairman | 66 | 10/02/2023 |
Naoki Okamura
BRD | Director/Board Member | 64 | 01/06/2019 |
| Director/Board Member | 59 | 01/06/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.86% | +6.82% | - | - | 27.22B | |
| +1.28% | +2.62% | +51.61% | +100.19% | 1,027B | |
| +1.10% | +1.45% | +52.49% | +67.37% | 651B | |
| +0.58% | +3.54% | +19.57% | +73.56% | 467B | |
| +0.26% | +5.43% | +38.78% | +40.69% | 350B | |
| +0.13% | +3.78% | +20.25% | +26.36% | 268B | |
| +0.51% | +6.85% | +11.22% | +16.61% | 257B | |
| +0.91% | -0.70% | +38.25% | +45.67% | 205B | |
| +1.29% | +2.60% | -27.73% | -56.39% | 190B | |
| +2.17% | +4.20% | +34.41% | +99.41% | 187B | |
| Average | +0.31% | +2.49% | +26.54% | +45.94% | 400.23B | |
| Weighted average by Cap. | -0.26% | +2.62% | +35.32% | +62.18% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 2,338B 15.01B 13.07B 12.37B 11.24B 21B 1,437B 21.1B 147B 56.97B 730B 56.37B 55.12B | 2,180B 13.99B 12.19B 11.53B 10.48B 19.58B 1,340B 19.67B 137B 53.12B 681B 52.56B 51.39B |
| Net income | 361B 2.32B 2.02B 1.91B 1.74B 3.24B 222B 3.26B 22.75B 8.8B 113B 8.71B 8.51B | 340B 2.18B 1.9B 1.8B 1.63B 3.05B 209B 3.07B 21.41B 8.28B 106B 8.19B 8.01B |
| Net Debt | -59.18B -380M -331M -313M -284M -531M -36.38B -534M -3.73B -1.44B -18.49B -1.43B -1.4B | -481B -3.08B -2.69B -2.54B -2.31B -4.32B -295B -4.34B -30.29B -11.71B -150B -11.59B -11.33B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/09/26 | $15.19 | +2.86% | 68,668 |
| 16/09/26 | $14.77 | -0.62% | 50,244 |
| 15/09/26 | $14.86 | +0.07% | 84,602 |
| 14/09/26 | $14.85 | +1.99% | 131,971 |
| 11/09/26 | $14.56 | +2.39% | 87,645 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4503 Stock
- ALPMY Stock
Select your edition
All financial news and data tailored to specific country editions
